C. Holohan, S. Van-schaeybroeck, D. B. Longley, and P. G. Johnston, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, vol.13, pp.714-726, 2013.

R. H. Wijdeven, B. Pang, Y. G. Assaraf, and J. Neefjes, Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics, Drug Resist. Updat, vol.28, pp.65-81, 2016.

X. D. Fu and M. Ares, Context-dependent control of alternative splicing by RNA-binding proteins, Nat. Rev. Genet, vol.15, pp.689-701, 2014.

S. Oltean and D. O. Bates, Hallmarks of alternative splicing in cancer, Oncogene, vol.33, pp.5311-5318, 2014.

C. J. David and J. L. Manley, Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged, Genes Dev, vol.24, pp.2343-2364, 2010.

H. Dvinge, E. Kim, O. Abdel-wahab, and R. K. Bradley, RNA splicing factors as oncoproteins and tumour suppressors, Nat. Rev. Cancer, vol.16, pp.413-430, 2016.

E. Kim, J. O. Ilagan, Y. Liang, G. M. Daubner, S. C. Lee et al., SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition, Cancer Cell, vol.27, pp.617-630, 2015.

C. L. Shirai, J. N. Ley, B. S. White, S. Kim, J. Tibbitts et al., Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo, Cancer Cell, vol.27, pp.631-643, 2015.

V. Visconte, N. Avishai, R. Mahfouz, A. Tabarroki, J. Cowen et al., Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron, Leukemia, vol.29, pp.188-195, 2015.

S. Jin, H. Su, N. T. Tran, J. Song, S. S. Lu et al., Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1, PLoS One, vol.12, p.175523, 2017.

S. M. Dehm, mRNA splicing variants: exploiting modularity to outwit cancer therapy, Cancer Res, vol.73, pp.5309-5314, 2013.

Z. Siegfried and R. Karni, The role of alternative splicing in cancer drug resistance, Curr. Opin. Genet. Dev, vol.48, pp.16-21, 2018.

B. Wang and N. Lee, Aberrant RNA splicing in cancer and drug resistance, Cancers (Basel), vol.10, p.458, 2018.

V. Pagliarini, C. Naro, and C. Sette, Splicing regulation: a molecular device to enhance cancer cell adaptation, Biomed. Res. Int, p.543067, 2015.

S. Calabretta, P. Bielli, I. Passacantilli, E. Pilozzi, V. Fendrich et al., Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells, Oncogene, vol.35, pp.2031-2039, 2016.

T. Liu, H. Sun, D. Zhu, X. Dong, F. Liu et al., TRA2A promoted paclitaxel resistance and tumor progression in triple-negative breast cancers via regulating alternative splicing, Mol. Cancer Ther, vol.16, pp.1377-1388, 2017.

A. M. Mohamed, M. Balsat, M. Thenoz, C. Koering, L. Payen-gay et al., Oncogene-and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML), Oncotarget, vol.7, pp.2889-2909, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01812676

R. Sciarrillo, A. Wojtuszkiewicz, I. E. Kooi, V. E. Gómez, U. Boggi et al., Using RNA-sequencing to detect novel splice variants related to drug resistance in in vitro cancer models, J. Vis. Exp, vol.1, p.201800088, 2016.

M. Dutertre, F. Z. Chakrama, E. Combe, F. O. Desmet, H. Mortada et al., A recently evolved class of alternative 3 -terminal exons involved in cell cycle regulation by topoisomerase inhibitors, Nat. Commun, vol.5, p.3395, 2014.

J. Millour, N. De-olano, Y. Horimoto, L. J. Monteiro, J. K. Langer et al., ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance, Mol. Cancer Ther, vol.10, pp.1046-1058, 2011.

C. Asencio, A. Chatterjee, and M. W. Hentze, Silica-based solid-phase extraction of cross-linked nucleic acid-bound proteins, Life Sci. Alliance, vol.1, 2018.

S. Shen, J. W. Park, Z. X. Lu, L. Lin, M. D. Henry et al., rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data, Proc. Natl. Acad. Sci. U.S.A, vol.111, pp.5593-5601, 2014.

C. Benoit-pilven, C. Marchet, E. Chautard, L. Lima, M. P. Lambert et al., Complementarity of assembly-first and mapping-first approaches for alternative splicing annotation and differential analysis from RNAseq data, Sci. Rep, vol.8, p.4307, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01924204

J. W. Park, S. Jung, E. C. Rouchka, Y. T. Tseng, and Y. Xing, ) rMAPS: RNA map analysis and plotting server for alternative exon regulation, Nucleic Acids Res, vol.44, pp.333-338, 2016.

C. Braeutigam, L. Rago, A. Rolke, L. Waldmeier, G. Christofori et al., The RNA-binding protein Rbfox2: An essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion, Oncogene, vol.33, pp.1082-1092, 2014.

X. Jin, Y. Wei, Y. Liu, X. Lu, F. Ding et al., Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/?-catenin signaling pathway in breast cancer, Cancer Med, vol.8, pp.1246-1257, 2019.

Q. Q. Li, J. Xu, . Da, W. J. Wang, X. X. Cao et al., Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells, Clin. Cancer Res, vol.15, pp.2657-2665, 2009.

P. S. Soon, E. Kim, C. K. Pon, A. J. Gill, K. Moore et al., Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells, Endocr. Relat. Cancer, vol.20, pp.1-12, 2013.

J. L. Bell, K. Wächter, B. Mühleck, N. Pazaitis, M. Köhn et al., , 2013.

, Post-transcriptional drivers of cancer progression?, mRNA-binding proteins (IGF2BPs), vol.70, pp.2657-2675

A. H. Mangs and B. J. Morris, ZRANB2: structural and functional insights into a novel splicing protein, Int. J. Biochem. Cell Biol, vol.40, pp.2353-2357, 2008.

B. Sundararaman, L. Zhan, S. M. Blue, R. Stanton, K. Elkins et al., Resources for the comprehensive discovery of functional RNA elements, Mol. Cell, vol.61, pp.903-913, 2016.

S. Chanarat and K. Sträßer, Splicing and beyond: the many faces of the Prp19 complex, Biochim. Biophys. Acta -Mol. Cell Res, vol.1833, pp.2126-2134, 2013.

F. E. Loughlin, R. E. Mansfield, P. M. Vaz, A. P. Mcgrath, S. Setiyaputra et al., The zinc fingers of the SR-like protein ZRANB2 are single-stranded RNA-binding domains that recognize 5 splice site-like sequences, Proc. Natl. Acad. Sci. U.S.A, vol.106, pp.5581-5586, 2009.

A. Basant and M. Glotzer, Spatiotemporal regulation of RhoA during cytokinesis, Curr. Biol, vol.28, pp.570-580, 2018.

Y. Zou, Z. Shao, J. Peng, F. Li, D. Gong et al., Crystal structure of triple-BRCT-domain of ECT2 and insights into the binding characteristics to CYK-4, FEBS Lett, vol.588, pp.2911-2920, 2014.

M. C. Srougi and K. Burridge, The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage, PLoS One, vol.6, p.17108, 2011.

D. He, J. Xiang, B. Li, and H. Liu, The dynamic behavior of Ect2 in response to DNA damage, Sci. Rep, vol.6, p.24504, 2016.

C. Mayor-ruiz, O. Dominguez, and O. Fernandez-capetillo, TrapSeq: An RNA sequencing-based pipeline for the identification of gene-trap insertions in mammalian cells, J. Mol. Biol, vol.429, pp.2780-2789, 2017.

Z. Zhu, D. Chen, W. Zhang, J. Zhao, L. Zhi et al., Modulation of alternative splicing induced by paclitaxel in human lung cancer, Cell Death Dis, vol.9, p.491, 2018.

Y. H. Yang, M. A. Markus, A. H. Mangs, O. Raitskin, R. Sperling et al., ZRANB2 localizes to supraspliceosomes and influences the alternative splicing of multiple genes in the transcriptome, Mol. Biol. Rep, vol.40, pp.5381-5395, 2013.

S. Ben-yehuda, I. Dix, C. S. Russell, M. Mcgarvey, J. D. Beggs et al., Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in Saccharomyces cerevisiae, Genetics, vol.156, pp.1503-1517, 2000.

O. Dahan and M. Kupiec, Mutations in genes of Saccharomyces cerevisiae encoding pre-mRNA splicing factors cause cell cycle arrest through activation of the spindle checkpoint, Nucleic Acids Res, vol.30, pp.4361-4370, 2002.

P. C. Chu, Y. C. Yang, Y. T. Lu, H. T. Chen, L. C. Yu et al., Silencing of p29 affects DNA damage responses with UV irradiation, Cancer Res, vol.66, pp.8484-8491, 2006.

P. C. Chu, T. Y. Wang, Y. T. Lu, C. K. Chou, Y. C. Yang et al., Involvement of p29 in DNA damage responses and Fanconi anemia pathway, Carcinogenesis, vol.30, pp.1710-1716, 2009.

C. H. Chen, P. C. Chu, L. Lee, H. W. Lien, T. L. Lin et al., Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response, PLoS One, vol.7, p.33538, 2012.

A. Maréchal, J. M. Li, X. Y. Ji, C. S. Wu, S. A. Yazinski et al., PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry, Mol. Cell, vol.53, pp.235-246, 2014.

N. Zhang, R. Kaur, S. Akhter, and R. J. Legerski, Cdc5L interacts with ATR and is required for the S-phase cell-cycle checkpoint, EMBO Rep, vol.10, pp.1029-1035, 2009.

L. Wan and J. Huang, The PSO4 protein complex associates with replication protein a (RPA) and modulates the activation of ataxia telangiectasia-mutated and RAD3-related (ATR), J. Biol. Chem, vol.289, pp.6619-6626, 2014.

G. Manic, A. Sistigu, F. Corradi, M. Musella, R. De-maria et al., Replication stress response in cancer stem cells as a target for chemotherapy, Semin. Cancer Biol, vol.53, pp.31-41, 2018.

A. M. Calcagno, C. D. Salcido, J. P. Gillet, C. P. Wu, J. M. Fostel et al., Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics, J. Natl. Cancer Inst, vol.102, pp.1637-1652, 2010.

S. Ohte, S. Kokabu, S. I. Iemura, H. Sasanuma, K. Yoneyama et al., Identification and functional analysis of Zranb2 as a novel Smad-binding protein that suppresses BMP signaling, J. Cell. Biochem, vol.113, pp.808-814, 2012.

X. Li, Y. Xue, X. Liu, J. Zheng, S. Shen et al., ZRANB2 / SNHG20 / FOXK1 Axis regulates Vasculogenic mimicry formation in glioma, J. Exp. Clin. Cancer Res, vol.38, p.68, 2019.

F. Shi, F. F. Cai, L. Cai, X. Y. Lin, W. Zhang et al., Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer, Oncotarget, vol.8, pp.88453-88463, 2017.

O. Thuerigen, A. Schneeweiss, G. Toedt, P. Warnat, M. Hahn et al.,

, Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer, J. Clin. Oncol, vol.24, pp.1839-1845

I. Passacantilli, P. Frisone, E. De-paola, M. Fidaleo, and M. P. Paronetto, HNRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells, Nucleic Acids Res, vol.45, pp.12270-12284, 2017.